Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer
Clinical trial NCT03507465 · UNKNOWN
Trial details
- NCT number
- NCT03507465
- Sponsor
- Guangdong Provincial People's Hospital
- Status
- UNKNOWN
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-29
- Primary completion
- 2019-11-29
- Enrollment
- 290
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.